Akari TX

NEW YORK and LONDON, January 29, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the …

[Read more...] about Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

NEW YORK and LONDON, January 27, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics to Participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day

NEW YORK and LONDON, January 5, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced an update …

[Read more...] about Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

NEW YORK and LONDON, December 7, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, provided an update …

[Read more...] about Akari Therapeutics Announces Update from Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

NEW YORK and LONDON, November 5, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics Announces Upcoming Data Presentations at the 57th American Society of Hematology Annual Meeting